Mayo Clinic Initiates Phase 2 Clinical Trial of Low-Dose Radiation Therapy for Indolent Non-Hodgkin Lymphoma
Exploring New Possibilities with Low-Dose Radiation Therapy
Mayo Clinic is conducting a Phase 2 clinical trial (NCT06386315) to evaluate the safety and efficacy of reduced-dose hypofractionated involved-site radiation therapy in patients with indolent B-cell non-Hodgkin lymphoma (iNHL). This study directly compares the therapeutic effects of the current standard regimen of 24 Gray (Gy) in 12 fractions with a low-dose regimen of 9 Gy in 3 fractions. Indolent lymphomas are highly sensitive to radiation, but high-dose radiation carries a risk of toxic side effects, making dose reduction a critical task that could significantly improve patients' quality of life.
Examining the Clinical Trial Design and Key Indicators
This Phase 2 clinical trial began in May 2024 and is currently recruiting patients, with an expected completion date of December 2026. The primary endpoint is the post-treatment toxicity profile and the incidence of adverse events. Secondary endpoints include objective response rate (ORR) and progression-free survival (PFS), which will be evaluated to confirm the non-inferiority of the low-dose treatment. The study plans to conduct long-term follow-up for up to 2 years to meticulously observe long-term safety and relapse rates.
Significant Impact on Patients and the Medical Community
If low-dose therapy proves to have similar tumor control efficacy to the standard treatment, it will significantly improve treatment convenience for patients. Reducing the number of radiation sessions from 12 to 3 will minimize the physical burden on elderly patients and reduce the incidence of radiation-related side effects. Furthermore, reducing the number of hospital visits for patients and increasing the turnover rate of medical resources will lead to significant reductions in healthcare costs and individual treatment expenses.
Leading the Paradigm Shift in Lymphoma Treatment
The global market for non-Hodgkin lymphoma (NHL) treatments is estimated at up to $14.1 billion by 2025 and is rapidly being reshaped by high-priced new drugs. However, radiation therapy remains a powerful local control option, and this clinical trial aims to establish a low-cost, high-efficiency treatment that can contribute to reducing healthcare costs. It also provides a safe and reliable alternative for patients who have limited access to expensive treatments, which has significant social value.
Setting a New Standard for Treatment
This study has the potential to change the standard protocols in radiation oncology by moving away from traditional high-dose treatments. If the safety and efficacy of low-dose therapy are demonstrated numerically, it will lead to revisions in clinical guidelines, allowing more patients to benefit from treatment early on. This will ultimately be an important milestone in establishing a patient-centered treatment standard that reduces toxicity.
This Phase 2 clinical trial aims to replace the existing 24 Gy standard radiation therapy with a 9 Gy reduced-dose hypofractionated regimen in the approximately $14.1 billion global non-Hodgkin lymphoma treatment market, with the goal of reducing toxicity while maintaining efficacy. From the researchers' perspective, it will be an opportunity to leverage the radiation response mechanism of indolent B-cell non-Hodgkin lymphoma to demonstrate the biological efficacy of the 9 Gy low-dose regimen and the protective effect on surrounding normal tissues. For medical professionals, the reduction in treatment sessions from 12 to 3 will maximize the operational efficiency of radiation equipment, reduce patient waiting times, and optimize clinical operations. From an investor's perspective, the focus is on the potential for establishing a cost-effective local control option compared to high-priced CAR-T therapies such as BMS's Breyanzi, thereby improving treatment access. In the long term, if Mayo Clinic leads the revision of treatment guidelines, reduced-dose radiation therapy may be incorporated as a standard treatment, which could change the landscape of the radiation equipment and related diagnostic markets.
Source: ClinicalTrials.gov (api_ct)